Fiorella Faienza, Matteo Lambrughi, Salvatore Rizza, Chiara Pecorari, Paola Giglio, Juan Salamanca Viloria, Maria Francesca Allega, Giovanni Chiappetta, Joëlle Vinh, Francesca Pacello, Andrea Battistoni, Andrea Rasola, Elena Papaleo, Giuseppe Filomeni
4 min
TRAP1 is a mitochondrial chaperone of the Hsp90 family known to support cancer cell survival by regulating mitochondrial metabolism and apoptosis. While it is known that TRAP1 can be S-nitrosylated at Cys501—a modification linked to its proteasomal degradation—the precise structural and functional consequences of this modification remained unclear. This study investigates how S-nitrosylation at Cys501 alters the chaperone's internal dynamics, ATPase activity, and its role in cell survival.
The researchers combined computational and experimental methods to characterize the impact of Cys501 S-nitrosylation. They performed molecular dynamics (MD) simulations on the full-length TRAP1 dimer to model how the modification at Cys501 propagates structural changes to distal sites, specifically the ATP-binding pocket. To validate these predictions, they generated a C501S mutant (which prevents S-nitrosylation) and compared its ATPase activity against the wild-type protein using colorimetric assays. Finally, they assessed the biological relevance of this modification in HeLa cells by measuring cell viability under apoptotic stress induced by staurosporine.
Computational analysis revealed that the S-nitrosylation site is integrated into a network of hub residues that transmit structural information across the protein. The modification at Cys501 is predicted to alter the open and closed conformational states necessary for the chaperone's ATPase cycle. Experimentally, the researchers confirmed that S-nitrosylation significantly decreases the ATPase activity of recombinant TRAP1. Conversely, the C501S mutant, which is immune to this redox regulation, displayed higher ATPase activity and conferred greater protection against staurosporine-induced cell death, suggesting that S-nitrosylation acts as a negative regulator of TRAP1's pro-survival function.
This study provides a mechanistic link between redox signaling and mitochondrial proteostasis. By demonstrating that S-nitrosylation acts as an allosteric switch to inhibit TRAP1, the findings suggest that nitric oxide levels in the mitochondria can directly dictate the chaperone's ability to support cancer cell survival. This highlights TRAP1 as a potential target for therapeutic strategies aimed at modulating the metabolic and survival pathways of tumor cells.
Alex: What about the mutation study?
Sam: They also swapped out the Cys501 site, replacing it with a chemically similar building block called serine. The protein structure stayed intact, but now the tag had nowhere to attach. When they tested this modified version, the brake no longer worked — the protein stayed active regardless. That confirmed Cys501 isn't just one of many possible targets. It's the essential switch.
Alex: So if you could trigger this brake inside a cancer cell — what does that actually mean for the cell?
Sam: It matters because TRAP1 does more than just fold proteins. It also blocks a process called apoptosis — which is essentially a cell's built-in self-destruct sequence. Healthy cells use apoptosis to eliminate themselves when they're damaged or no longer needed. Cancer cells often suppress it to keep growing, and TRAP1 is one of the tools they use to do that. So if you stiffen TRAP1 and shut it down, you're potentially removing the shield that protects the cancer cell from its own self-destruction.
Alex: You're not attacking the cancer directly — you're taking away its defenses.
Sam: That's a good way to put it. And the reason this approach is worth exploring is precision. Rather than a broad attack on all rapidly dividing cells — which is what many current treatments do, with significant side effects — this targets a specific mechanism that cancer cells rely on more heavily than healthy ones. It's worth noting, though, that these findings come from cell-based tests. Confirming that the same pathways behave this way in more complex biological systems will be an important next step.
Alex: It's a good reminder of how much complexity is packed into a single protein. A tiny chemical tag, one specific site, and the whole machine changes.
Sam: That's exactly what the research illustrates. Proteins aren't static shapes — they're dynamic, interconnected systems. A change at one point can ripple through the entire structure. Understanding those connections is what opens the door to more targeted approaches in cancer research.
Alex: Thanks for listening to ResearchPod.